BioCentury | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

...candidate, an option to acquire the BioMotiv company under pre-agreed terms. Details were not disclosed. KemPharm...
...licensed development and commercialization rights from KemPharm Inc. (NASDAQ:KMPH) for two ADHD candidates, KP415 and KP484. KemPharm...
...$483 million in regulatory and sales milestones plus royalties. GPC has an option for other KemPharm...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Co. Ltd. (Tokyo:4528) Selinexor Treat penta-refractory multiple myeloma (MM) PDUFA date; MAA action 7/6/19; YE19 KemPharm Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...II data Early 2019; YE19 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Selinexor Liposarcoma Phase III data YE19 KemPharm Inc....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...MAA 12/20/18; YE18 Kala Pharmaceuticals Inc. (NASDAQ:KALA) Inveltys (KPI-121 0.25%) Dry eye Submit NDA 4Q18 KemPharm Inc....
BioCentury | Jul 27, 2018
Clinical News

KemPharm's ADHD candidate meets in Phase III

...to 13 hours) vs. placebo (p<0.01 for all). KP415 is an extended-release prodrug of methylphenidate. KemPharm Inc....
...Permanent Product Measure of Performance (PERMP) score Status: Phase III data Milestone: Submit NDA (1Q19) Jennie Walters KP415 KemPharm Inc....
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...Novartis AG (NYSE:NVS; SIX:NOVN) Ruxolitinib Steroid-refractory acute graft-versus-host disease (GvHD) Ph III REACH1 data 2Q18 KemPharm Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...May Juno Therapeutics Inc. (NASDAQ:JUNO) JCAR017 Relapsed or refractory B cell NHL Submit BLA 2H18 KemPharm Inc....
BioCentury | Dec 30, 2016
Clinical News

KP415: Preliminary Ph I KP415.101 data

...KP415 under fasted conditions was generally well tolerated with no serious adverse events reported. Additionally, KemPharm...
...mg dose of ADHD drug Concerta methylphenidate from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). KemPharm Inc....
...pharmacokinetics Status: Preliminary Phase I data Milestone: Complete Pivotal trial (2017); submit NDA (2018) Jaime De Leon KP415 KemPharm Inc....
BioCentury | Oct 31, 2016
Company News

Acura, KemPharm deal

...Acura granted KemPharm rights to develop and commercialize up to three immediate-release candidates using Acura’s version...
...rights to develop and commercialize up to three immediate-release candidates using Acura’s version abuse-deterrent technology. KemPharm...
...from the deal. KemPharm declined to disclose additional terms. Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. KemPharm Inc....
BioCentury | Jul 11, 2016
Finance

Shedding red

...of IW-9179 after the compound fails in a Phase IIa trial to treat diabetic gastroparesis KemPharm Inc....
Items per page:
1 - 10 of 57
BioCentury | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

...candidate, an option to acquire the BioMotiv company under pre-agreed terms. Details were not disclosed. KemPharm...
...licensed development and commercialization rights from KemPharm Inc. (NASDAQ:KMPH) for two ADHD candidates, KP415 and KP484. KemPharm...
...$483 million in regulatory and sales milestones plus royalties. GPC has an option for other KemPharm...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Co. Ltd. (Tokyo:4528) Selinexor Treat penta-refractory multiple myeloma (MM) PDUFA date; MAA action 7/6/19; YE19 KemPharm Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...II data Early 2019; YE19 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Selinexor Liposarcoma Phase III data YE19 KemPharm Inc....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...MAA 12/20/18; YE18 Kala Pharmaceuticals Inc. (NASDAQ:KALA) Inveltys (KPI-121 0.25%) Dry eye Submit NDA 4Q18 KemPharm Inc....
BioCentury | Jul 27, 2018
Clinical News

KemPharm's ADHD candidate meets in Phase III

...to 13 hours) vs. placebo (p<0.01 for all). KP415 is an extended-release prodrug of methylphenidate. KemPharm Inc....
...Permanent Product Measure of Performance (PERMP) score Status: Phase III data Milestone: Submit NDA (1Q19) Jennie Walters KP415 KemPharm Inc....
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...Novartis AG (NYSE:NVS; SIX:NOVN) Ruxolitinib Steroid-refractory acute graft-versus-host disease (GvHD) Ph III REACH1 data 2Q18 KemPharm Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...May Juno Therapeutics Inc. (NASDAQ:JUNO) JCAR017 Relapsed or refractory B cell NHL Submit BLA 2H18 KemPharm Inc....
BioCentury | Dec 30, 2016
Clinical News

KP415: Preliminary Ph I KP415.101 data

...KP415 under fasted conditions was generally well tolerated with no serious adverse events reported. Additionally, KemPharm...
...mg dose of ADHD drug Concerta methylphenidate from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). KemPharm Inc....
...pharmacokinetics Status: Preliminary Phase I data Milestone: Complete Pivotal trial (2017); submit NDA (2018) Jaime De Leon KP415 KemPharm Inc....
BioCentury | Oct 31, 2016
Company News

Acura, KemPharm deal

...Acura granted KemPharm rights to develop and commercialize up to three immediate-release candidates using Acura’s version...
...rights to develop and commercialize up to three immediate-release candidates using Acura’s version abuse-deterrent technology. KemPharm...
...from the deal. KemPharm declined to disclose additional terms. Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. KemPharm Inc....
BioCentury | Jul 11, 2016
Finance

Shedding red

...of IW-9179 after the compound fails in a Phase IIa trial to treat diabetic gastroparesis KemPharm Inc....
Items per page:
1 - 10 of 57